Stocks and InvestingStocks and Investing
Fri, October 30, 2020
Thu, October 29, 2020
Wed, October 28, 2020

Colin Bristow Initiated (VRTX) at Strong Buy and Held Target at $287 on, Oct 28th, 2020


Published on 2024-10-27 14:31:58 - WOPRAI, Colin Bristow
  Print publication without navigation


Colin Bristow of UBS, Initiated "Vertex Pharmaceuticals Incorporated" (VRTX) at Strong Buy and Held Target at $287 on, Oct 28th, 2020.

Colin has made no other calls on VRTX in the last 4 months.



There are 10 other peers that have a rating on VRTX. Out of the 10 peers that are also analyzing VRTX, 3 agree with Colin's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $249 on, Monday, October 19th, 2020
  • Geoffrey Porges of "SVB Leerink" Maintained at Hold with Decreased Target to $267 on, Thursday, October 15th, 2020
  • Brian Abrahams of "RBC Capital" Maintained at Hold and Held Target at $276 on, Sunday, October 4th, 2020


These are the ratings of the 7 analyists that currently disagree with Colin


  • Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Decreased Target to $305 on, Thursday, October 15th, 2020
  • Alethia Young of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $305 on, Friday, July 31st, 2020
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $315 on, Friday, July 31st, 2020
  • Gena Wang of "Barclays" Maintained at Buy with Increased Target to $315 on, Friday, July 31st, 2020
  • Paul Matteis of "Stifel" Maintained at Strong Buy with Increased Target to $309 on, Friday, July 31st, 2020
  • Evan Seigerman of "Credit Suisse" Maintained at Buy with Increased Target to $328 on, Monday, July 20th, 2020
  • Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $330 on, Thursday, July 2nd, 2020